Abstract: Objective：To explore the short-term efficacy and safety of apatinib in the treatment of platinum-resistant ovarian cancer. Methods：Patients with platinum-resistant ovarian cancer treated at the First Affiliated Hospital of Zhengzhou University from July 2015 to January 2019 were collected and divided into 2 groups according to the treatment protocol: simple chemotherapy group (gemcitabine+oxaliplatin) and apatinib combined chemotherapy group (apatinib+gemcitabine+oxaliplatin). The objective remission rate (ORR) and disease control rate (DCR) were evaluated and the incidence of adverse reactions was compared in the 2 groups. Results：The ORR (52.4% vs. 24.0%) and DCR (61.9% vs. 32.0%) in the apatinib combined chemotherapy group were better than those in the simple chemotherapy group, and the level of CA125 after treatment was significantly lower than that in the simple chemotherapy group (P＜0.05). The incidence of hypertension and skin reaction of hand and foot in the apatinib combined chemotherapy group was higher than that in the simple chemotherapy group (P＜0.05), and all adverse reactions could be alleviated after symptomatic support treatment. Conclusions：Apaintib combined with chemotherapy is effective and safe in treating platinum-resistant ovarian cancer.

Key words: Ovarian neoplasms, Drug resistance, neoplasm, CA-125 antigen;, Treatment outcome;, Safety;, Apatinib